NOVAVAX, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12.99 USD | -9.79% |
|
+46.28% | +170.62% |
| May. 16 | Transcript : Novavax, Inc. Presents at Bank of America Health Care Conference 2024, May-15-2024 03:00 PM | |
| May. 14 | Global markets live: Apple, Sony, Vodafone, Booking, Walmart... |  |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
Financials (USD)
| Sales 2024 * | 952M | Sales 2025 * | 586M | Capitalization | 1.83B |
|---|---|---|---|---|---|
| Net income 2024 * | 18M | Net income 2025 * | -116M | EV / Sales 2024 * | 1.04 x |
| Net cash position 2024 * | 837M | Net cash position 2025 * | 704M | EV / Sales 2025 * | 1.92 x |
| P/E ratio 2024 * |
205
x | P/E ratio 2025 * |
-23.7
x | Employees | 1,543 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 94.14% |
More Fundamentals
* Assessed data
More news
Latest transcript on Novavax, Inc.
More recommendations
More press releases
More news
| 1 day | -9.79% | ||
| 1 week | +46.28% | ||
| Current month | +200.00% | ||
| 1 month | +233.93% | ||
| 3 months | +212.26% | ||
| 6 months | +126.70% | ||
| Current year | +170.62% |
1 week
9.52
15.00
1 month
3.8615.00
Current year
3.5315.00
1 year
3.5315.00
3 years
3.53277.80
5 years
3.53331.68
10 years
3.53331.68
| Managers | Title | Age | Since |
|---|---|---|---|
John Jacobs
CEO | Chief Executive Officer | 57 | 23-01-22 |
John Trizzino
PSD | President | 64 | 14-03-09 |
James Kelly
DFI | Director of Finance/CFO | 58 | 21-08-15 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Richard Rodgers
BRD | Director/Board Member | 57 | 22-10-28 |
Gregg Alton
BRD | Director/Board Member | 58 | 20-10-31 |
David Mott
BRD | Director/Board Member | 58 | 20-06-15 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.31% | 17 M€ | +7.73% | - | |
| 0.15% | 0 M€ | 0.00% | - | |
| 0.13% | 2 M€ | -.--% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-17 | 13.01 | -9.65% | 13,906,467 |
| 24-05-16 | 14.4 | +11.63% | 24,873,452 |
| 24-05-15 | 12.9 | -4.30% | 26,671,753 |
| 24-05-14 | 13.48 | +2.82% | 56,549,364 |
| 24-05-13 | 13.11 | +47.64% | 123,507,768 |
Delayed Quote Nasdaq, May 17, 2024 at 04:00 pm EDT
More quotes
Novavax, Inc. is a biotechnology company, which discovers, develops and commercializes vaccines to prevent serious infectious diseases. The Company offers a differentiated vaccine platform that combines a recombinant protein approach, advanced nanoparticle technology and its patented Matrix-M adjuvant to enhance the immune response. It has one commercial program, for vaccines to prevent COVID-19, which includes Nuvaxovid prototype COVID-19 vaccine (NVX-CoV2373 or prototype vaccine) and Nuvaxovid updated COVID-19 vaccine (NVX-CoV2601 or updated vaccine) (collectively, COVID-19 Vaccine). The Company is advancing the development of other vaccine candidates, including its COVID19-Influenza Combination (CIC) vaccine candidate and additional vaccine candidates. Its COVID-19 Vaccine and its other vaccine candidates incorporate the Companyâs proprietary Matrix-M adjuvant to enhance the immune response and stimulate higher levels of functional antibodies and induce a cellular immune response.
Calendar
2024-08-05
- Q2 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
13.01
USD
Average target price
19.75
USD
Spread / Average Target
+51.81%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +170.62% | 1.83B | |
| -0.09% | 42.12B | |
| +49.62% | 42.05B | |
| -4.96% | 29.18B | |
| +11.18% | 26.02B | |
| -21.95% | 18.9B | |
| +8.61% | 13.21B | |
| +24.73% | 12.17B | |
| +28.31% | 12.16B | |
| -6.26% | 11.42B |
- Stock Market
- Equities
- NVAX Stock
